VAS3947

• CAT Number: I037973
• CAS Number: 869853-70-3
• Molecular Formula: C14H10N6OS
• Molecular Weight: 310.33
• Purity: 98%
• Synonyms: VA-S3947; VA S3947; VAS3947
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Store at -20°C
• IUPAC Name: 3-Benzyl-7-(2-oxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine
• InChI: InChI=1S/C14H10N6OS/c1-2-4-10(5-3-1)8-20-12-11(18-19-20)13(17-9-16-12)22-14-15-6-7-21-14/h1-7,9H,8H2
• InChIKey: JVZDLDFNSCFLPM-UHFFFAOYSA-N
• SMILES: C12=NC=NC(SC3=NC=CO3)=C1N=NN2CC4=CC=CC=C4

VAS3947（Cat No.:I037973）is a potent and specific inhibitor of NADPH oxidase activity, with low micromolar concentrations sufficient for its action, without interfering with ROS detection or the activities of XOD or eNOS. In other words, VAS3947 selectively targets NADPH oxidase, an enzyme that produces reactive oxygen species (ROS), while leaving other important cellular processes unaffected. This makes VAS3947 a promising candidate for the treatment of diseases related to ROS production, such as cardiovascular disease and inflammation.

Reference

1: Hecht N, Terveer N, Schollmayer C, Holzgrabe U, Meinel L. Opening NADPH oxidase inhibitors for in vivo translation. Eur J Pharm Biopharm. 2017 Jun;115:206-217. doi: 10.1016/j.ejpb.2017.03.001. Epub 2017 Mar 8. PubMed PMID: 28284727.
2: Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012 May-Jun;56(5-6):216-31. doi: 10.1016/j.vph.2012.02.012. Epub 2012 Mar 3. Review. PubMed PMID: 22405985; PubMed Central PMCID: PMC3378316.
3: Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010 Oct;161(4):885-98. doi: 10.1111/j.1476-5381.2010.00920.x. PubMed PMID: 20860666; PubMed Central PMCID: PMC2970907.